Alzheimer’s Medication

New Treatments to Slow Alzheimer's Available Now

Is your loved one’s memory fading? Access two new Alzheimer’s treatments only available at our private UK clinics, approved by the MHRA. Whether you’re from the UK or not, you can benefit from innovative therapies designed to slow cognitive decline and improve quality of life.

As global leaders in Alzheimer’s, we are more experienced than any other clinic in the UK in providing both of these new treatments for Alzheimer’s Disease.

Fill out our form or call us now and we’ll be in touch to see if we can help.

 

Call Now: 0800 802 1030

Explore the Page:

Making revolutionary changes in Alzheimer’s treatment

Making a real change in any disease requires not only new revolutionary medications, but also the ability to detect the disease at the earliest possible moment – ideally, even before symptoms begin – to slow, stop, and eventually prevent the onset and progression of symptoms.

As the most experienced provider in the field, Re:Cognition Health can now prescribe medication for Alzheimer’s Disease privately, following MHRA approval.

What are the new Alzheimer’s medications?

Both drugs are monoclonal antibodies designed to target and clear amyloid-beta plaques in the brain, a hallmark of Alzheimer’s. By reducing these toxic proteins, they help slow cognitive decline and disease progression, offering hope for patients in the early stages of the condition.

 

Why patients are travelling to the UK for treatment

These groundbreaking treatments are not yet available in many European countries, and it remains uncertain when they will become widely accessible in the NHS.

Patients from across Europe and beyond are now travelling to our UK clinics to access these innovative therapies and expert care. If you or a loved one could benefit from early treatment, we encourage you to get in touch and find out how we can help.

 

Who is eligible for these new Alzheimer’s treatments?

Call us today to discuss if you or a loved one are suitable for the new Alzheimer’s treatments.

  • Eligibility: Confirmation of elevated amyloid protein by Amyloid PET or CSF analysis is mandatory.
  • Treatment: Bi-weekly intravenous infusion or monthly intravenous infusion with monitoring via MRI scans
  • Required: A study program partner (family member or friend) for regular contact.
  • Follow-Up: Recommended amyloid re-assessment at 12 months, then at 18 or 24 months.

 

How soon can I be seen?

We know how important early detection is so we do not have lengthy waiting lists. We get prospective patients screened as soon as possible for an assessment and schedule a follow-up appointment afterwards.

Alzheimer's: A Turning Point?

Re:Cognition Health featured, recently, in BBC One’s Panorama, “Alzheimer’s: A Turning Point?”. This follows the journey of volunteers at several Re:Cognition Health’s UK centres testing new generation medications over the past few years. During this time our teams have gain unparalleled experience in managing, safely,  individuals taking these medications and their potential side effects. For those in the UK, you can still watch this on BBC iPlayer, and see first hand how the medications have been demonstrated to slow progression of Alzheimer’s and its symptoms.